TMRW Appoints 23andMe Vice President of Business Development, Emily Drabant Conley Ph.D., to Board of Directors
NEW YORK, June 19, 2019 /PRNewswire/ -- TMRW, creator of the first Robotic Process Automation (RPA) platform specifically for in vitro fertilization (IVF), announced today that Emily Drabant Conley, Ph.D., Vice President, Business Development at 23andMe, has been named to the company's Board of Directors. Dr. Conley joins TMRW's other recent board appointees: Shake Shack CFO Tara Comonte and former Elle Editor-in-Chief Robbie Myers.
Dr. Conley joined 23andMe's leadership team in 2010 and has been instrumental to the company's rapid growth and revolutionary business strategies. Dr. Conley has led the company in identifying and establishing global partnerships with top pharmaceutical, biotech, CPG, retail and healthcare companies as well as crucial alliances in academia. In 2018, her efforts and leadership helped 23andMe secure a $300m equity stake and collaborative partnership with GlaxoSmithKline to develop innovative genetic therapies.
"Emily is universally recognized as an extraordinary leader across healthcare, academia and business. Her patient-centric approach to innovation, scale and partnership has helped 23andMe become a massive global phenomenon," said Joshua Abram, TMRW's Founder and Co-CEO. Jeff Port, M.D., a TMRW Co-Founder and its Chief Medical Officer added: "Current IVF best practice has evolved over the last decade from a singular focus on embryology to incorporating the science of cryobiology and genetics. Emily has been a pioneer in the rapidly evolving science of applied genetics. We are honored by her choice to join TMRW's Board of Directors and look forward to receiving her counsel and direction."
"TMRW has a great leadership team, and an innovative approach to solving existing deficiencies in the management and storage of vitrified embryos and gametes," Dr. Conley said. "At 23andMe, we've made access to fertility care part of our employee benefits, and we see that leading a broader trend. As access to fertility care expands globally, the need for an effective and automated platform to manage this process is imperative. For TMRW, the implications of being the trusted custodian of the cells that will result in the birth of 200-300 million people in coming decades is staggering. I look forward to being involved in TMRW's growth, innovation and success."
Before joining 23andMe, Dr. Conley spent 10 years conducting research that combined genetics and neuroimaging in an effort to better understand neuropsychiatric disease. She was a Research Fellow at the National Institute of Mental Health and has co-authored more than 30 academic publications. She holds a Ph.D. in Neuroscience from Stanford University, and a B.A. in Psychology and Business from Vanderbilt University.
Dr. Conley's joining TMRW's Board of Directors was announced alongside the appointment of Bill Garbarini, Tim Sharp and Ann Watson to TMRW's Executive Leadership team. Their roles at the company and relevant experience include:
TMRW has created the first fully Robotic Process Automation (RPA) platform designed specifically for the fertility community. Already experiencing rapid market adoption, leading IVF doctors and clinicians have embraced TMRW's platform because it replaces the current outdated analog IVF cryo-preservation and tissue management system by providing the world's first automated cryostorage and RFID enabled digital chain of custody for embryos and gametes. TMRW's proprietary software is constantly vigilant, delivering up to 17,000 automated daily environmental "health checks" to ensure the safety and security of the world's most precious cells.
TMRW's founders, Joshua Abram, Alan Murray (co-CEOs) and Jeff Port, M.D. (Chief Medical Officer) are serial tech and life sciences entrepreneurs. Their immediate prior ventures sold for a combined sum of more than $1 billion.
View original content to download multimedia:http://www.prnewswire.com/news-releases/tmrw-appoints-23andme-vice-president-of-business-development--emily-drabant-conley-phd-to-board-of-directors-300871372.html